Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 November 2023 | Story Valentino Ndaba | Photo SUPPLIED
UFS KovsieCare GBV Social Media
The UFS is joining forces with the international community during the annual 16 Days of Activism against Gender-Based Violence.

As the world will soon commemorate the 16 Days of Activism against Gender-Based Violence (GBV) campaign, the University of the Free State (UFS) joins the fight against this pervasive issue. Dedicated to eradicating GBV and fostering a safe environment, the institution has pledged an unwavering commitment to a zero-tolerance stance against all forms of GBV.

The 16 Days of Activism against Gender-Based Violence is an annual global initiative that starts on 25 November 2023 – International Day for the Elimination of Violence against Women – and concludes on 10 December 2023 – Human Rights Day. The theme for this year, ‘Accelerating actions to end gender-based violence and femicide: leaving no one behind’, emphasises the need for a comprehensive, inclusive effort to combat GBV. 

Legislation addressing GBV

Gender-based violence, rooted in the systemic imbalance of power and authority, manifests in multifaceted forms that encompass emotional, physical, financial, and sexual abuse, among others. Recognising the gravity of this issue, parliament has enacted laws, including the Domestic Violence Act of 1998 and the Children's Act of 2005, striving to safeguard individuals from such atrocities and championing fundamental human rights.

The UFS, aligned with parliament's vision and encapsulating its own Vision 130 within the 2023-2028 Strategic Plan, remains steadfast in its dedication to fostering a culture of accountability, care, and social justice within its staff and student community. 

The significance of activism

Dr Lentsu Nchabeleng, Deputy Director in the Gender Equality and Anti-Discrimination Office (GEADO), emphasised the pivotal role of the 16 Days of Activism in societal progress. “Advocacy plays an important role in prevention by promoting education and awareness. Advocacy challenges harmful societal norms and stereotypes that contribute to gender-based violence and can help foster a culture of equality and respect," she stated.

Useful resources

The UFS has provided resources for the staff and student community, including frequently asked questions (FAQs) about GBV and sexual offences, aiming to clarify these important matters. Help and reporting avenues for GBV and sexual misconduct are available on the Bloemfontein and South campuses, with similar support available on the Qwaqwa Campus, underscoring the university's dedication to a safe and supportive environment for all. 

Click to download the resource documents:

Important contacts 

The university has also implemented support systems, including dedicated 24-hour toll-free helplines for reporting GBV and sexual offenses, underscoring its commitment to addressing this epidemic.

  • GEADO toll-free: 0800 204 682
  • UFS Student Careline toll-free: 0800 00 6363

 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept